Artrya Limited (ASX:AYA), a medical technology company commercialising its Salix® AI-powered cloud platform for coronary artery disease assessment, disclosed at its 2026 Annual General Meeting that it has signed multi-year commercial contracts with five U.S. health systems and added HonorHealth as a new potential customer, with the AGM held at the company's West Perth office on 13 November 2026.

Key Points

  • Artrya has signed multi-year commercial contracts with five U.S. health systems, with Salix® integrated at Tanner Health and Northeast Georgia, while Cone Health is progressing toward deployment.
  • Huntsville became the first SAPPHIRE research partner to convert to a commercial contract, with HonorHealth added during the AGM week as a new potential customer.
  • The U.S. market for CCTA scans is currently valued at approximately US$4.4 billion per year, according to the Chair's address.
  • The Centres for Medicare and Medicaid Services announced an increase in CCTA reimbursement from US$356 to US$395 for CY27, and confirmed rates for Plaque and Flow assessments at US$950 and US$850 respectively.

U.S. Market Opportunity and CMS Reimbursement Rates

At the AGM, the Chair stated that the U.S. market for Coronary Computed Tomography Angiography scans is currently worth approximately US$4.4 billion per year. The American College of Cardiology and the American Heart Association have recommended CCTA as the first-line diagnostic test for patients with chest pain. The Centres for Medicare and Medicaid Services announced an increase in CCTA scan reimbursement from US$356 to US$395 for CY27, and confirmed reimbursement rates for Plaque and Flow assessments at US$950 and US$850 respectively, according to the Chair's address to shareholders.

Commercial Contracts and Foundation Partner Deployments

The Chair reported that Artrya has signed multi-year commercial contracts with five U.S. health systems. The Salix® platform has been integrated at Tanner Health and Northeast Georgia, two of the company's three U.S. foundation partners, while Cone Health is progressing toward deployment. Huntsville was disclosed as the first SAPPHIRE research partner to convert to a commercial contract. The company stated it has a deliberate strategy to build its sales pipeline by converting SAPPHIRE research partners into commercial customers. All three foundation partners operate under Category 1 codes that are largely covered by insurers, according to the filing.

HonorHealth Added as New Potential Customer

During the week of the AGM, Artrya disclosed that HonorHealth was added as the first from a new group of potential customers arising from inbound enquiries. The company stated it continues to see strong inbound enquiry driven by endorsement from early customers across the U.S. healthcare sector. The Chair's address described the company's Salix® Coronary Anatomy platform as a single enterprise-wide platform designed to manage clinical workflow for chest pain patients, with the company targeting full integration of Salix® Coronary Anatomy, Salix® Coronary Plaque, and Salix® Coronary Flow across its foundation customers once FDA clearance is obtained for Coronary Flow.